Alisertib is an orally administered small molecule inhibitor of Aurora A kinase. Aurora kinases are involved in cell division and inhibiting them may result in the inhibition of cell proliferation. In this Phase I study Alisertib is administered in patients with advanced solid tumors or relapsed lymphoma with varying degrees of hepatic function.
BAX69 is an anti-macrophage migration inhibitory factor (anti-MIF) antibody. MIF is a pro-inflammatory cytokine that is up-regulated in many human cancers and contributes to growth, angiogenesis and migration of cancer cells. BAX69 is administered intravenously every 2 weeks in a 28 day cycle in patients with malignant solid tumors.
BGJ398 is an orally bioavailable inhibitor of human fibroblast growth factor receptor (FGFRs) with potential antiangiogenic and antineoplastic activities. BYL719 is an oral selective PI3K a isoform inhibitor. In this Phase I study BGJ398 in combination with BYL719 is administered in patients with select solid tumors that have PIK3CA gene mutation with or without FGFR genetic alteration.
Cabazitaxel is a new taxoid, which promotes tubulin assembly and has shown strong antitumor activity against a broad spectrum of tumor models including those sensitive as well as resistant or refractory to other taxanes such as docetaxel. This is a Phase I safety and pharmacokinetic study of XRP6258 (Cabazitaxel) in advanced solid tumor patients with varying degrees of hepatic impairment.
Carfilzomib is a selective proteasome inhibitor. This Phase I study is evaluating the safety of Carfilzomib in patients with advanced solid tumors or hematological malignancies and varying degrees of hepatic impairment. It is administered on days 1, 2, 8, 9, 15, and 16 during a 28 day cycle.
CBL0137 is a small molecule in the carbazole family affecting p53 and NF-kappa B signal transduction pathways. It is administered intravenously on days 1, 8 and 15 every 28 days in patients with metastatic or advanced solid tumors and refractory lymphomas.
Crizotinib is orally bioavailable ALK and c-MET/HGFR receptor tyrosine kinases inhibitor. This Phase I study evaluates the effect of hepatic impairment on the pharmacokinetics and safety of Crizotinib in advanced cancer patients with solid tumors.
DKN-01 is humanized monoclonal antibody directed against DKK-1 protein which is an inhibitor of the Wnt/ß-catenin signaling pathway important in cell growth and differentiation. In this Phase I study DKN-01 is administered with weekly Paclitaxel in patients with relapsed or refractory esophageal cancer or gastro-esophageal junction cancer.
GSK2118436 is an orally bioavailbale inhibitor of B-raf protein which may inhibit the proliferation of tumor cells with mutated BRAF gene. It is administered in patients with V600 BRAF mutation positive tumors. Previous exposure to BRAF inhibitors is allowed.
Halaven is a synthetic analogue of the marine spong natural product halichondrinB. As an inhibitor of microtubules it blocks the cell division and leads to apoptosis of the cancer cells. In this study Halaven is administered on days 1 and 8 of a 21 day cycle in patients with solid tumors who also have impaired renal function.
IMGN 529 consists of CD37 targeting humanized monoclonal antibody and cytotoxic maytansinoid DM1. In this Phase I study IMGN529 is administered intravenously every 3 weeks to patients with relapsed or refractory Non-Hodgkin’s lymphoma.
IMGN853 is an immunoconjugate consisting of the humanized monoclonal antibody against folate receptor 1 (FOLR1) conjugated to the cytotoxic maytansinoid DM4. It is administered once every 21 days intravenously in patients with advanced solid tumors with FOLR1 expression. Tumor types which have a high incidence of FOLR1 positivity (serous or endometroid epithelial ovarian cancer, serous endometrial cancer, NSCLC of adenocarcinoma and bronchoalveolar cancer and clear cell renal carcinoma) can enroll without the specific testing.
LDE225 is an oral selective Smo antagonist that downregulates the Hedgehog signal transduction pathway. In this Phase I study the patients with advanced solid tumors receive LDE225 with Warfarin or Bupropion to evaluate the drug-drug interaction.
M402 is a heparin sulfate mimetic designed to have antitumor effect without the anticoagulant activity. In this Phase I/II study M402 is administered as daily subcutaneous injection with Gemcitabine in patients with metastatic pancreatic cancer who have not received prior chemotherapy.
MLN7243 is a small molecule inhibitor of ubiquitin-activating enzyme (UAE) with potential antineoplastic activity. MLN7243 is administered intravenously in patients with advanced solid tumors using 2 different schedules. Treatments will be on days 1, 4, 8 and 11 on a 21 day cycle or days 1, 8 and 15 on a 28 day cycle.
MLN9708 is an oral proteasome inhibitor. In this Phase I/Ib study it is administered in patients with relapsed/refractory multiple myeloma and advanced solid tumors who have normal renal function or severe renal impairment.
Description: This is a Phase I/II study of RAD001 (everolimus) for patients with glioblastoma or gliosarcoma (brain tumor). Patients are randomized to receive RAD 001 with the standard treatment of radiation plus temozolomide (oral chemotherapy) or to receive the standard treatment of radiation plus temozolomide alone.
TVB-2640 is FASN (Fatty Acid Synthase) inhibitor. FASN is an enzyme important in tumor metabolism, lipid signaling and tumor cell survival. In this Phase I study it is administrated orally in patients with solid tumors.